PATENT CLAIM ANALYSIS

Application Number: 16142831
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-05
Patent Classification: ["424", "139100"]

Abstract:
Anti-CD40 antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.

Claim (Index 6):
A lyophilised formulation prepared by lyophilising an aqueous formulation having a pH of 6.0 and comprising\n (i) an anti-CD40 antibody wherein the antibody has a concentration of 150 mg/ml, and wherein said anti-CD40 antibody includes heavy chain CDR1, CDR2 and CDR3 of SEQ ID NOs 3, 4 and 5 respectively, and light chain CDR1, CDR2 and CDR3 of SEQ ID NOs: 6, 7 and 8, (ii) 270 mM sucrose as a stabiliser, (iii) 30 mM histidine as a buffering agent, and (iv) 0.06% polysorbate 20 as a surfactant.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 97.0
- Lexical Diversity: 1.61017
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15881195', '14452647', '14946170', '13991984', '13295141']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7393442446567122
- 35 USC 102 Novelty (BERT): 0.5954557108214312
- Combined Prediction Score: 0.7249553912731841
- Mean Citation Score: 354.338944
- Max Citation Score: 494.10074
- Similarity Product: 481.4084900155663

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test